Peer-reviewedCC BYBiomedicines
Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape
- 1Department of Haematology, Ramón y Cajal University Hospital/Ramón y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain;
- 2Department of Haematology, , 28222 Majadahonda, Spain;
Related
- Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report
- Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report
- USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival.
- Economic Burden of Chronic Lymphocytic Leukaemia in Australia
- Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups
BibTeX
@article{marquetpalomanes2026richter,
title = {{Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape}},
author = {Juan Marquet-Palomanes and Fernando Martin-Moro and Jose A. Garcia-Vela},
journal = {Biomedicines},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13701445},
note = {CC BY},
}
RIS
TY - JOUR
TI - Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape
AU - Juan Marquet-Palomanes
AU - Fernando Martin-Moro
AU - Jose A. Garcia-Vela
PY - 2026
DA - 2026/10/01
JO - Biomedicines
UR - https://europepmc.org/article/PMC/PMC13701445
SN - 2227-9059
ER -